- medical research
Grey Wolf Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of GRWD5769 in Patients with Advanced Solid Tumours
OXFORD, UK and MELBOURNE, AUSTRALIA, March 28, 2023 /PRNewswire/ -- Grey Wolf Therapeutics, a biotechnology company focused on generating entirely novel anti-tumour immune responses through targeted cancer neoantigen creation, today announced dosing of the first patient in the initial monotherapy module of an adaptive Phase 1/2 clinical trial evaluating GRWD5769, the company's investigational first-in-class ERAP1 inhibitor. The trial, named...
Read more